Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: primary biliary cholangitis (PBC) patients with a suboptimal response to ursodeoxycholic acid (UDCA) have a significantly worse survival rate. Fenofibrate has been shown to improve the short-term biochemical response in this group of patients. However, there is limited data available on the safety and efficacy of its long-term use, especially in patients with cirrhosis. Methods:in this retrospective cohort study, fenofibrate was given to PBC patients with a suboptimal response to at least 12 months of UDCA (13-15 mg/kg/d) therapy. Biochemistry data, GLOBE score and UK-PBC risk score at baseline and at different time points of treatment were compared. The safety profiles were also compared between cirrhotic and non-cirrhotic patient groups. Results:fenofibrate (200 mg/day) was given to 39 PBC patients with a suboptimal response to UDCA (15 cirrhotic and 24 non-cirrhotic patients). In the 26 patients who completed more than one year of combination therapy, the alkaline phosphatase (ALP) levels were 215 (185, 326) U/l, 122 (110, 202) U/l, 128 (106, 194) U/l, 124 (100, 181) U/l and 120 (82, 168) U/l, at baseline, three months, six months, 12 months and 24 months, respectively. All p values were < 0.01 when compared to baseline values. After two years of combination therapy, the UK-PBC risk score and GLOBE score did not significantly improve. The overall rates of adverse events were not significantly different between the cirrhotic and non-cirrhotic group. The elevation of liver enzymes was the most frequent side effect (n = 7), leading to a discontinuation in four patients. Furthermore, after two years of combination therapy, the serum creatinine levels and estimated glomerular filtration rates (eGFR) were significantly worse in both groups. CONCLUSION: fenofibrate add-on therapy could improve ALP and γ-GT levels in both non-cirrhotic and cirrhotic PBC patients with a suboptimal response to UDCA. However, patients need to be monitored carefully for a potential liver injury and nephrotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · cited 1×
“Furthermore, these patients have a significantly worse survival rate compared to those with a good response (2-5).”
BackgroundBiochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 1×
“Furthermore, these patients have a significantly worse survival rate compared to those with a good response (2-5).”
BackgroundLammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498 · cited 1×
“5 times the upper normal limit (UNL) after at least one year of treatment with UDCA at 13-15 mg/kg/day (13,14).”
BackgroundNew Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study
Zhao, Y. Y., Weir, M. A., Manno, M., Cordy, P., Gomes, T., Hackam, D. G., Juurlink, D. N., Mamdani, M., Moist, L., Parikh, C. R., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00401 · Cited by 258
Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186 · cited 2×
“Recent studies have also shown that adding fenofibrate to UDCA could improve clinical symptoms, as well as the biochemical and immunological response, with good safety profiles (8-11).”
BackgroundMychaleckyj, J. C., Craven, T., Nayak, U., Buse, J., Crouse, J. R., Elam, M., Kirchner, K., Lorber, D., Marcovina, S., Sivitz, W., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1811 · Cited by 149
Cheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13465 · Cited by 139
Zhang, L.-N., Shi, T.-Y., Shi, X.-H., Wang, L., Yang, Y.-J., Liu, B., Gao, L.-X., Shuai, Z.-W., Kong, F., Chen, H., et al. (2013) · Hepatology · doi:10.1002/hep.26322 · Cited by 113 · cited 1×
“Furthermore, these patients have a significantly worse survival rate compared to those with a good response (2-5).”
BackgroundSelf-citationLens, S., Leoz, M., Nazal, L., Bruguera, M., & Parés, A. (2014) · Liver International · doi:10.1111/liv.12290 · Cited by 107 · cited 1×
“5 times the upper normal limit (UNL) after at least one year of treatment with UDCA at 13-15 mg/kg/day (13,14).”
Background
Cited by
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Self-citationVuppalanchi, R., Caldwell, S. H., Pyrsopoulos, N., deLemos, A. S., Rossi, S., Levy, C., Goldberg, D. S., Mena, E. A., Sheikh, A., Ravinuthala, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.025 · Cited by 79
Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
Dohmen, K., Onohara, S.-Y., & Harada, S. (2021) · The Korean Journal of Gastroenterology · doi:10.4166/kjg.2021.092 · Cited by 18
Guoyun, X., Dawei, D., Ning, L., Yinan, H., Fangfang, Y., Siyuan, T., Hao, S., Jiaqi, Y., Ang, X., Guanya, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.948362 · Cited by 13
“Furthermore, some relevant clinical studies (Cheung et al., 2016; Duan et al., 2018; Hegade et al., 2016) and new evaluation criteria including Robins-I (Sterne et al.”
BackgroundMethod
Metadata
- Authors
- Duan, W., Ou, X., Wang, X., Wang, Y., Zhao, X., Wang, Q., Wu, X., Zhang, W., Ma, H., You, H., & Jia, J.
- Venue
- Revista Española de Enfermedades Digestivas
- Published
- 2018
- Volume
- 110
- Issue
- 9
- Pages
- 557-563
- ISSN
- 1130-0108 (ISSN-L)
- OpenAlex
- W2801166767
- Cited by
- 30
- References
- 12
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. https://app.cochat.ai/papers/10.17235/reed.2018.5533/2018
- The paper
- Duan, W., Ou, X., Wang, X., Wang, Y., Zhao, X., Wang, Q., Wu, X., Zhang, W., Ma, H., You, H., & Jia, J. (2018). Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. Revista Española de Enfermedades Digestivas. https://doi.org/10.17235/reed.2018.5533/2018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.